A large number of neuroimaging studies have detected brain abnormalities in first-episode
schizophrenia both before and after treatment, but it remains unclear how these …

Duration of untreated psychosis (DUP) is defined as the time from the onset of psychotic
symptoms until the first treatment. Studies have shown that longer DUP is associated with …

Background Several studies have suggested that the retina structure is affected in
schizophrenia spectrum disorders (SSD). We aimed to investigate the location and size of …

Background: Emerging evidence supports the antipsychotic effect of cannabidiol, a non-
intoxicating component of cannabis, in people with psychosis. Preclinical findings suggest …

Abstract Treatment resistant (TR) psychosis is considered to be a significant cause of
disability and functional impairment. Numerous efforts have been made to identify the …

Hippocampal volume is smaller in schizophrenia, but it is unclear when in the illness the
changes appear and whether specific regions (anterior, posterior) and subfields (CA1 …

Disrupted serotonergic and glutamatergic signaling interact and contribute to the
pathophysiology of schizophrenia, which is particularly relevant for the hippocampus where …

Background Subcortical volumetric abnormalities in schizophrenia, bipolar disorder and
major depressive disorder (MDD) have been consistently found on a single-diagnosis basis …

Introduction The impact of the clinical high-risk for psychosis (CHR-P) construct is
dependent on accurately predicting outcomes. Individuals with brief limited intermittent …

Hippocampal hyperactivity is a novel pharmacological target in the treatment of
schizophrenia. We hypothesized that levetiracetam (LEV), a drug binding to the synaptic …